Michael Skogen
About Michael Skogen
Michael Skogen serves as the Vice President of Sales at Parse Biosciences, bringing extensive experience in sales and scientific research. He has held various roles in notable companies such as Illumina and NanoString Technologies, and has a strong academic background in biology and finance from the University of Delaware.
Current Role at Parse Biosciences
Michael Skogen serves as the Vice President of Sales at Parse Biosciences, a position he has held since 2021. In this role, he is responsible for leading the sales team and driving strategic growth initiatives within the company. His experience in sales operations and analytics supports his leadership in this fast-paced environment.
Previous Experience at Illumina
Prior to his current position, Michael worked at Illumina from 2009 to 2017. He began as a Senior Inside Sales Representative and progressed to the role of Senior Inside Sales Manager. Over his eight years at Illumina, he contributed to sales growth and developed key strategies for customer engagement.
Career at NanoString Technologies, Inc.
Michael Skogen held multiple roles at NanoString Technologies, Inc. from 2017 to 2021. He served as Associate Director of Global Consumable Sales and Operations for two years before advancing to Director of Global Consumable Sales. His leadership in these roles focused on enhancing sales operations and expanding market reach.
Educational Background
Michael studied at the University of Delaware, where he earned a Bachelor of Science in Biology from 2002 to 2006. He continued his education at the same institution, obtaining a Master's degree in Molecular Biology and Genetics from 2006 to 2007. Additionally, he completed an MBA at the Alfred Lerner College of Business & Economics at the University of Delaware from 2007 to 2009.
Research Experience
Michael has a background in scientific research, having worked as a researcher at the University of Delaware from 2007 to 2008. He also served as an undergraduate researcher from 2004 to 2006. His research experience spans over four years and includes contributions to advancements in cancer treatment and stem cell therapy.